Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Cejemly (sugemalimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

CStone Pharma, Pfizer

Drug class:

PD-L1 inhibitor

Related drugs:

‹

atezolizumab (236)

durvalumab (198)

envafolimab (6)

IO102-IO103 (4)

atezolizumab/hyaluronidase (1)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

›

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1
No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	sugemalimab Sensitive: B - Late Trials sugemalimab Sensitive : B	sugemalimab Sensitive: B - Late Trials sugemalimab Sensitive : B
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	sugemalimab Sensitive: B - Late Trials sugemalimab Sensitive : B	sugemalimab Sensitive: B - Late Trials sugemalimab Sensitive : B
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	sugemalimab Sensitive: B - Late Trials sugemalimab Sensitive : B	sugemalimab Sensitive: B - Late Trials sugemalimab Sensitive : B
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3